Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
verfasst von:
Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran
Following publication of the original article [1], the authors identified an error in the author names of Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen and Chandrasekhar Chikatapu. The given names and family names were erroneously transposed.
Further to this, figure 1 has been updated. The line colors in “C” section for “Poor” and “Unknown” have been changed to align with Figure B and legend to match the line colors.
The author group has been updated above and the original article [1] has been corrected.
Fig. 1
Kaplan-Meier plot for PFS for (A) all patients, (B) MSKCC risk categories, and (C) IMDC risk categories (FAS)
×
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
verfasst von
Mustafa Erman Bivas Biswas Pongwut Danchaivijitr Lingwu Chen Yoke Fui Wong Tarek Hashem Chun Sen Lim Bulent Karabulut Hsiao-Jen Chung Chandrasekhar Chikatapu Sara Ingles Khemaies Slimane Ravindran Kanesvaran
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
